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Summary 
Epithelial ovarian cancer (EOC) is a highly lethal malignancy due to late 
diagnosis and early relapse associated with development of chemoresistance. So 
far, the origin of drug resistance is not completely understood and several 
mechanisms seem to be responsible for this process including the ability of 
cancer cells to modify/reprogram cellular metabolism. Aberrant choline 
metabolism, characterized by increased phosphocholine (PCho) levels sustained 
by enhanced choline kinase (ChoK) activity, is a new cancer metabolic 
hallmark that can be monitored by Magnetic Resonance Spectroscopy (MRS) 
and that reflects the interactions between oncogenic signaling and cellular 
metabolism. EOC possesses an altered MRS-choline profile, characterized by 
increased PCho content to which mainly contribute over-expression and 
activation of Choline kinase-alpha (ChoKα). The project aimed to investigate 
the biological and clinical relevance of increased ChoK expression and activity 
in EOC. We showed that transient CHKA silencing induced: a significant 
reduction in PCho accumulation as assessed by MRS analysis; an inhibition of 
in vitro cell growth; down modulation of genes related to inflammation and 
EOC aggressiveness; a significantly reduced cell motility and invasion and a 
significant increase of sensitivity to platinum, paclitaxel and doxorubicin even 
in a drug-resistant context.  Since the dynamics of biological effects related to 
CHKA silencing could not possibly be detectable by transient RNAi, we stably 
downregulated ChoKα mRNA expression using a lentiviral vector, expressing 
GFP and specific CHKA shRNA, in two EOC cell lines, INTOV11 and 
SKOV3. In both transduced cell lines, we confirmed the data obtained with the 
transient downmodulation, as reduction of PCho content, inhibition of in vitro 
cell growth, reduction of invasive potential and migration capability. 
Furthermore, a significant decrease of in vivo tumor growth (sub-cutaneous 
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injection) was evident in both sh-CHKA cellular models as compared to their 
controls. The global metabolic profiles of sh-CHKA and control EOC cell lines, 
performed with the Metabolon technology platform, revealed in both cellular 
models an alteration of glutathione metabolism, commonly characterized by a 
decrease of reduced glutathione (GSH) content in shCHKA cells as compaired 
to their controls. Interestingly, sh-CHKA showed an increased sensitivity to 
drug treatment (platinum and doxorubicin) suggesting that CHKA knocking 
down may change antioxidant cellular defense thus increasing drug sensitivity. 
Since the GSH intracellular levels are well known to interfere with treatment 
efficacy of several DNA damaging drugs, we have investigated whether the 
alteration of GSH/GSSG levels dependent upon CHKA silencing is the 
mechanism by which response/resistance to DNA-damaging drugs is affected. 
Artificial reduction of intracellular GSH in wild type EOC cells phenocopied 
CHKA silencing effects while restoration of GSH levels in CHKA silenced 
cells caused a recovery of the wt phenotype by rescuing drug resistance. The 
concurrent modulation of active ROS species following CHKA silencing 
demonstrates the direct involvement of oxidative stress pathway regulation by 
ChoKα expression.  
Finally, in order to investigate the putative role of CHKA in EOC pathogenesis 
we performed an in silico analysis on seven public data sets of gene expression 
profile, including 698 EOC patients and we found a progressive increase of 
CHKA expression along EOC grading. Interestingly the CHKB expression in 
the same samples showed an opposite trend. Given these premises, we propose 
that a metabolic approach to EOC treatment might have the potential to address 
some of the issues that contribute to the high EOC lethality and open the way 
for the validation of ChoKα as a new therapeutic target to be used alone or in 
combination with conventional drugs for EOC treatment. 
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Introduction  
1. Ovarian Cancer 
1.1 Clinical aspects 
Although its incidence is quite low, EOC is the leading cause of death from 
gynecologic cancers (1). Symptoms associated with EOC are typically 
nonspecific and their association to the tumor is often not recognized therefore, 
more than two thirds of EOC cases are diagnosed when the disease has 
progressed to late stages (III/IV) (2), dropping 5-year survival rate to 
approximately 33%. Besides stage and histologic grade at diagnosis, the 
presence or absence of residual disease after debulking surgery remains an 
important prognostic factor for EOC. Surgery is followed by a combination of 
platinum - and taxane-based chemotherapy as first-line treatment for advanced 
EOC, yielding response rates of over 80% (3). However, most of the patients 
will eventually relapse with a median progression-free survival of 18 months. 
The length of the disease-free period following response to platinum 
compounds can be used to categorize patients into groups with different 
prognosis: platinum-sensitive, -resistant and -refractory disease (4). Many 
efforts have been made to overcome chemoresistance following front-line 
treatment. Different drug combinations are indeed available to treat relapsing 
patients, including some molecular targeted agents like: angiogenesis, PARP or 
tyrosine  kinase inhibitors (5); however, clinical responses to these drugs are 
only partial and new approaches to improve EOC patients treatment with better 
design of therapeutic trials are still needed (6). 
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1.2 Histological subtypes and origins of EOC 
Historically, EOCs were thought to arise from ovarian surface epithelial cells, 
leading to four major cell types: serous, endometrioid, clear cell and mucinous. 
Although differences in biology and response to therapy were recognized, it 
was thought that these cell types reflected morphologic variants of the same 
disease, and cell type was not a selection criteria for type of treatment. There 
are now  increasing evidences that major EOC cell types arise from distinct, 
often non ovarian, precursor lesions (Figure 1) (7). Recent pathological, 
immune-histochemical and molecular studies have changed this view, “Shifting 
the paradigm” (8), from one disease model toward a set of unique diseases of 
diverse origin and biology, linked primarily by ovarian localization, with 
profound therapeutic implications. The EOC are primarily classified by cell 
types in: high grade serous, mucinous, endometroid and clear cells 
corresponding, according to the molecular (assessed by gene expression profile) 
and morphological features similar to those of the different epithelia in the 
organs of the female reproductive tract (Figure 1). 
 
 
 
 
 
 
 
 
 
Figure 1. The origins of ovarian cancer (from Vaughan S. et al 2011). 
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 Serous EOC: the most common type. It derives from epithelial cells 
covering ovary surface and/or from the distal fallopian tube, even if at 
the moment the real contribute of this two compartments to the origin of 
this tumor is not completely understood (7),(9).  
 Mucinous EOC: represent 5–10% of all malignant ovarian neoplasms, 
are characterized by cells resembling either those of the endocervical 
epithelium or, more frequently, those of the intestinal epithelium 
(intestinal type). 
 Endometrioid EOC: the second most common malignant EOC, are 
characterized by cells resembling those of the endometrium and they are 
associated with endometriosis.  
 Clear Cell EOC: little is known about the development and progression 
of this type of EOC. In some cases they are associated to endometriosis, 
atypical noninvasive endometriosis has been shown to be linked to Clear 
Cell Carcinoma (CCC) through demonstration of identical mutations in 
both components.  
 
Based on cell type, origin and molecular features a new paradigm for the 
pathogenesis and origin of EOC has been now proposed on the basis of a 
dualistic model of carcinogenesis. Accordingly, EOC have been categorized 
into two categories corresponding to the two main pathways of tumorigenesis, 
designated as types I and II (Figure 2).  
Type I tumors comprise Low grade serous Carcinomas (LGSCs), endometroid, 
clear cell and mucinous carcinomas. These tumors constitute only 25% of EOC 
with a 5 year survival of about 55%. They are generally indolent, with a good 
prognosis, tumor masses are localized to one ovary (stage I) and are associated 
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with frequent KRAS, BRAF, CTNNB, PTEN and PIK3C genetic alterations, 
with rare mutations in TP53 gene (8). 
Type II tumors comprise High Grade serous Carcinomas
cancers present at more advanced stages and grow a
approximately 75% of ovarian tumors, and are responsible for 90
deaths. They are driven by multiple areas of amplification and deletion; almost 
all HGSC have mutations in the p53 gene, and
showed mutations or epigenetic alterations in
(8),(10). Carcinomas diagnosed in the past as poorly different
endometrioid or mixed, exhibiting p53 mutations
 
 
 
 
 
 
 
 
 
 
Figure 2. The histologic types of EOC and their associated molecular genetic change
(from Kurman and Shih, Hum Path 
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2. Alteration of cellular metabolism: a new cancer hallmark. 
Cancer is a complex and heterogeneous disease characterized by specific 
genomic alteration and deregulation of important molecular events related to 
apoptosis, cell cycle control, cell differentiation, response to growth-
promoting/inhibiting signals and migration capability. All these alterations are 
included in the first classification of cancer hallmarks (11). This classification 
has been recently revised to include two other important cancer features: 
stemness and metabolism alteration (12). The introduction of  magnetic 
resonance spectroscopy (MRS) for tumor studies helped to identify a potential 
source of novel indicators of tumor progression and response to therapy: among 
them the abnormal choline metabolism, characterized by increased 
phosphocholine (PCho) and total choline-containing compounds (13) has been 
identified in different type of tumors including EOC (14).  
2.1 Choline transporters 
Choline is an essential nutrient that is derived from diet and transported into the 
cells. Four different types of choline-transporting transmembrane systems have 
been implicated in cancer: high-affinity choline transporters (CHTs), choline 
transporter-like proteins (CTLs), organic cation transporters (OCTs) and 
organic cation/carnitine transporters (OCTNs). CTL1 was shown by microarray 
analysis to be expressed in cancers of the central nervous system, breast and 
prostate, as well as in leukemia, and to be highly expressed in melanoma, renal 
and colon cancer (15). Human pulmonary adenocarcinoma tissues overexpress 
CTL1 and to a lesser extent OCT3, compared with matched normal tissues (16). 
In breast cancer cells the increased PCho level is predominantly determined by 
enhanced Cho transport mediated by OCT2 and CHT1 (17).  
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2.2 Phosphatidylcholine metabolism 
Phosphatidylcholine (PtdCho) is the most important membrane lipid in 
eukaryotic cells. The biosynthesis of PtdCho in eukaryotes is done by two 
distinct pathways: cytidine disulphate (CDP)-choline pathway (also known as 
Kennedy pathway) and  phosphatidylethanolamine (PE) methylation pathway. 
The de novo synthesis of PtdCho from choline via the CDP–choline pathway is 
present in all mammalian cells and consists of three steps: in the first reaction, 
choline kinase (ChoK) converts choline to phosphocholine (PCho). In the 
second reaction of the pathway, CTP-PCho-cytidylyltransferase (CT) converts 
CTP and PCho to CDP–choline. In the third and final step, CDP – choline: 1,2-
diacyl glycerol choline phosphotransferase (CPT) converts CDP–choline and 
Diacylglycerol (DAG) to PtdCho (Figure 4)(18). In addition to the Kennedy 
pathway, hepatocytes have an additional pathway to make PtdCho by 
methylation of PE (Figure 5) (19). Another PtdCho biosynthetic pathway is 
related to sphingomyelin metabolism (SM) (Figure 5). This pathway is often 
involved in the process of apoptosis. Since PtdCho donates PCho to ceramide in 
the final step of SM synthesis, inhibition of PtdCho synthesis may lead to a 
decrease of SM and accumulation of pro-apoptotic ceramides (19).  
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Figure 4: Schematic representation of PtdCho biosynthesis and catabolism. Metabolites: 
CDP-Cho, cytidine diphosphate choline; Cho, choline; DAG, diacylglycerol; FFA, free fatty 
acid; G3P, sn-glycerol-3-phosphate; GPC, glycerophosphocholine; PA, phosphatidate; PCho, 
phosphocholine. Enzymes: ck, choline kinase; ct, cytidylyltransferase; lpl, lysophospholipase; 
pct, phosphocholine transferase; pd, glycerophosphocholine phosphodiesterase; pla, 
phospholipase A1 and phospholipase A2;  plc, phospholipase C; pld, phospholipase D. 
(Modified from Iorio et al 2005) 
 
 
 
 
 
 
 
 
Figure. 5:.Pathways for the synthesis of PtdCho, PE and SM. Abbreviations: CK, choline 
kinase; CPT, cholinephosphotransferase; CT, CTP:phosphocholine cytidylyltransferase; DAG, 
diacylglycerol; PtdCho, phosphatidylcholine; PE, phosphatidylethanolamine; PEMT, 
phosphatidyl- ethanolamine-N-methyltransferase; PS, phosphatidylserine; PSD, 
phosphatidylserine decarboxylase; PSS1&2, phosphatidylserine synthase1&2; SM, 
sphingomyelin; SMase, sphingomyelinase; SMsyn, sphingomyelin synthase. (Modified from 
Zheng Cui et al 2002).  
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We focused our attention on Kennedy pathway, because we and others 
identified several enzymes such as choline kinase-α (CHKα), phosphocholine 
cytidylyl-transferase (CCT), phosphatidylcholine specific phospholipase D 
(PC-PLD) and phosphatidylcholine phospholipase C (PC-PLC), as 
overexpressed and/or activated in cancer suggesting their potential use as 
prognostic markers.  
2.3  PtdCho biosynthetic pathway (Kennedy’s Pathway). 
Choline kinase (Chok) catalyses the first reaction of Kennedy’s Pathway: 
phosphorylation of free choline using ATP as a phosphate donor, to produce 
PCho (see Fig 4). Chok was first described in 1953 by Wittenberg and 
Kornberg (20)and first cloned in 1992 (21). At least three isoforms of Chok 
exist in mammalian cells, encoded by two genes: CHKA and CHKB (22). The 
two functional isoforms, Chokα1 and Chokα2, are derived from CHKA by 
alternative splicing. Distribution of isoform’s dimer population is still not 
known but ChoKα is the major form of Chok which positively correlates with 
malignant phenotype of cancer cells (23).  Studies with knockout mice 
demonstrate that CHKA, but not CHKB loss, is embryonically lethal suggesting 
that CHKB cannot compensate for the loss of CHKA, which is necessary to 
sustain PtdCho biosynthesis (24). Overexpression of Chokα, but not of Chokβ, 
has been reported in several human tumour-derived cell lines of multiple 
origins, as well as in biopsies of lung, colon and prostate carcinomas compared 
with matched normal tissue from the same patient (23),(25),(26). Besides 
expression, also Chokα activity was shown to be increased in colon (27), in 
breast (28) and in ovarian (29)   carcinomas compared with normal tissue.  This 
large body of literature suggests that Chokα expression and activity is 
Anna Granata 
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associated with increased cancer cell proliferation and malignancy, making it a 
potential prognostic marker for some cancers.  
Phosphocholine cytidylyltransferase (ct) catalyses the synthesis of CDP 
choline and PPi from PCho and cytidine triphosphate (CTP) (see Figure 4). 
CDP-choline is the most highly activated Cho intermediate of the Kennedy 
pathway, directly used to form the membrane lipid PtdCho. This enzyme exists 
as an inactive soluble form and as an active lipid-bound form in the nuclear 
membrane. Four highly homologous isoforms of this enzyme exist in 
mammalian cells: ctα (also known as PCYT1A), which is ubiquitously 
expressed and active as a homodimer; and ctβ1, ctβ2 and ctβ3 (which are splice 
variants of PCYT1B) that exhibit tissues pecific expression. In the literature is 
reported that an increasing of Chokα and ct expression and activity in colon 
cancer  results in elevated PCho and PtdCho levels, thereby facilitating 
enhanced cell growth and proliferation (13). 
2.4 PtdCho catabolic pathways 
PC-specific phospholipase D (PC-PLD) is one of the enzyme involved in 
PtdCho catabolism; it catalyzes PtdCho hydrolysis producing phosphatidic acid 
and intracellular free Choline. Two isoforms of mammalian PC-PLD have been 
isolated and sequenced: PLD1 predominantly localized to Golgi membranes, 
and PLD2 associated to both Golgi and plasma membranes. Location of both 
PLD enzymes may depend on the cell type and physiological state of the cells. 
PLD1 and PLD2 are crucial in cell proliferation, survival signaling, cell 
transformation and tumor progression (13). Increased expression and activity of 
PLD1 has been well documented in gastric and breast cancer. Recently it has 
been reported a strong correlation between expression of Chokα and PLD1 with 
breast cancer malignancy. These two enzymes were found to be interactive: 
down-regulation of either one of the two enzymes induced increased expression 
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of the other one and their simultaneous silencing in a breast cancer cell line 
increased apoptosis. These data support multiple targeting of enzymes in 
choline phospholipid metabolism as a strategy for cancer treatment (30).  
PC-specific phospholipase C (PC-PLC) also mediates PtdCho hydrolysis 
producing PCho and DAG, an important second messenger for cells. Since the 
1990s, a growing body of evidence has pointed, to the implication of PC-PLC 
in proliferation, differentiation, and apoptosis of mammalian cells. Indeed, this 
enzyme has been implicated in many cellular processes crucial for cell signaling 
(31),(32). 
Additional catabolic enzymes, such as PC-specific phospholipase A1 (PC-
PLA2), PC-specific phospholipase A2 (PC-PLA2), lysophospholipase, GPC 
phosphodiesterase (GPC-PDE), may also be important in sustaining the 
cholinic phenotype by altering levels of PCho, GPC and Cho. GPC-PDE 
catalyzes the degradation of GPC to free choline and glycerol-3-phosphate. 
GPC-PDE probably participates in the regulation of choline phospholipid 
metabolism in breast cancer in cooperation with CHKA and PLD1 (33). The 
expression of cytosolic phospholipase A2 (PLA2; also known as PLA2G4A) 
was decreased in breast cancer cells(13) and may modulate the cellular MRS-
detected GPC levels (24). 
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3 Aberrant choline metabolism in EOC 
My research group in collaboration with the Istituto Superiore di Sanità in 
Rome, by analyzing tumor cells MRS spectra profiles, identified for the first 
time in EOC an abnormal concentration of PCho. Analysis of expanded total 
choline spectral profiles showed that the relative areas of signal components 
due to individual choline metabolites (GPC, PCho, and choline) changed in the 
progression from non-tumoral ovarian surface epithelial cells or immortalized 
cell variants (EONT) to EOC cells (14), with PCho becoming predominant in 
carcinoma cells (Figure 6).  
 
 
Figure 6. Altered Choline metabolism in EOC cells. left panel : Representative expanded 
region of H1NMR spectra profiles (700 MHz) of total choline in aqueous extracts of EONT 
(OSE and immortalized cells variants IOSE and hTERT) cells and EOC cell line (IGROV1). 
Right panel: Quantification of aqueous metabolites (mean±SD) in EOC and EONT cells. 
(Modified from Podo , NMR 2011).  
 
 
Major contribution to PCho accumulation may derive from alternative or 
combined activation of enzymes involved in PtdCho biosynthesis and/or 
catabolism: Chok and PC-PLC. By multidisciplinary approaches, it has been 
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found that in EOC cells there is an iper-expression and iper-activation of Chok 
compared to the normal counterpart (Figure 7). 
 
 
 
Figure 7: ChoK activity and expression are increased in EOC cells. A: ChoK protein 
expression by Western blotting. B: Chok densitometric evaluation referred to GAPDH, relative 
to EONT cells. C: Chok enzymatic activity in EOC cells compared to EONT cells. (Modified 
from Iorio et al, 2010) 
 
 
Gene expression analysis of the enzyme involved in metabolic and catabolic 
pathway showed that only CHKA was iper-expressed whereas the expression of 
others enzyme involved in Kennedy’s pathway, as well as choline transporters 
and enzyme involved in catabolic pathway (PLD, PLA1 and PLA2) remained 
unchanged (Figure 8). 
Anna Granata 
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Figure 8: Gene expression of enzymes involved in PtdCho biosynthetic and catabolic 
pathways. A: RT-qPCR analysis of enzymes' expression in EOC (OSE cells used as an internal 
calibrator; horizontal line at quantification level = 1). For each gene, the mean value (±SD) of 
the analyzed EOC cell lines is reported. B: microarray analysis of choline transporters (dotted 
line, sensitivity threshold). C: RT-qPCR analysis of PLD1 and PLD2 in EOC cells (OSE used 
as an internal calibrator; horizontal line at quantification level = 1). D: Gene expression of 
PLA1 and of PLA2 isoforms. The dotted line represents sensitivity threshold. (Modified from 
Iorio et al 2010).  
 
Among the enzymes involved in catabolic pathways only PC-PLC is directly 
involved in PCho accumulation. Currently, the mammalian PC-PLC has not 
been cloned and its sequence is unknown. The only available knowledge is 
related to its protein expression and activity in cancer cells. Indeed, this enzyme 
is iper-expressed and iper-activated in EOC cell compared to normal 
counterparts (29),(31) . EOC cell exposure to the PC-PLC inhibitor D609, 
abolished the activity of this enzyme and reduced intracellular PCho level 
A
D
B
C
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PC-PLC  activity
(without altering GPC and free Cho contents) suggesting that PC-PLC 
contributes to the intracellular PCho pool in EOC (Figure 9).  
 
 
 
 
 
 
 
 
Figure 9: Activation of PC-PLC in EOC cells. A: Expression (left) and activity (right) of PC-
PLC in cell lysates of nontumoral (OSE, IOSE, hTERT) and EOC cell lines. B: PC-PLC 
activity (left) and PCho content (right) in OVCAR3 cells following incubation in the absence 
(CTRL) or presence of D609 (53μg/mL, 24 h). Inset: representative 1H NMR tCho profile in 
aqueous extracts showing PCho drop following D609 treatment (Modified from Spadaro et al, 
2008 and Iorio et al 2010). 
 
4 Choline kinase as a novel therapeutic target  
Several studies have demonstrated that ChoKα plays an important role in cell 
transformation inducing in vivo tumorigenesis (34), (28). Furthermore, ChoKα 
is overexpressed in different type of tumors, including colon, breast, lung, 
prostate, ovary (25),(35),(14),(29). Based on these observations, ChoKα has 
been proposed as a novel molecular target to develop a new antitumoral 
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strategy. Available ChoKα inhibitors (ChoKIs) are derivates of the 
Hemicolinium-3 (HC3), a known ChoK inhibitor with a high neurotoxicity in 
vivo (36),(37). MN58b was identified as a first generation of HC3 derivate with 
potent antiproliferative activity in vitro and efficient antitumoral activity in vivo 
in nude mice xenografts (38). MN58b has been used as model for a new 
generation of compounds (39),(40). A second generation of ChoKIs has been 
synthesized to improve tolerability in mice. TCD-717 has been selected among 
several molecules because it provided the best results in vitro and in vivo (38). 
TCD-717 is currently undergoing a Phase I clinical trials for toxicity testing in 
cancer patients. Both drugs, MN58b and TCD-717, being derived from HC3 are 
considered choline competitive inhibitors at choline binding pocket and at the 
moment are not commercially available. A small molecule (CK37) is also 
available as able to inhibit tumor growth in preclinical models (41).  Silencing 
of CHKA has been proposed as an alternative strategy to inhibit Chokα, to be 
used alone or in combination with conventional drugs. Silencing of CHKA in 
human breast cancer cells by RNA interference (RNAi) decreased cellular 1H-
MRS-detectable PCho levels and cell proliferation with induction of 
differentiation in highly invasive and metastatic human breast cancer cells and 
tumour xenografts (42). Non-invasive 31P-MRS detected a reduction in PCho 
levels following intravenous injection of a lentiviral vector that delivered short 
hairpin RNA targeting CHKA in a breast cancer xenograft model (43). ChoKα 
inhibition is highly specific for tumor cells, since primary cells are reversibly 
arrested in G1 and are able to recover their growth kinetics once the drug is 
removed. In fact, the targeting of ChoK by RNA interference (RNAi), results in 
decreased PCho and tCho levels in human breast cancer cells while leaving 
human mammary epithelial cells unaffected (44) opening an important 
therapeutic window for the development of a pharmacological intervention 
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directed to this enzyme. These data suggest that inhibiting Chokα in solid 
tumors might represent a new anticancer approach. 
5 Mechanisms of cancer cell resistance to chemotherapy 
Drug induced resistance is frequently observed in clinical oncology and can 
significantly limit the clinical response to subsequent chemotherapy.  Cancer 
patients respond significantly to selected anticancer agents during initial 
treatment. However, most of the cancers acquire resistance to the drug 
following long term treatment, thus compromising patient’s response.  Cancer 
cells undergo continuous genetic changes in order to escape natural 
mechanisms and drug-induced death. Continuous use of  chemotherapy  
induces  selective  pressure  on  tumor  cells,  with possible development of 
drug resistance in  cell  sub-populations that  can  lead  to  “Multidrug  
resistance  phenomenon”.  Cancer  cell resistant  to  one  drug  can  display  
cross-resistance  to  numerous  drugs,  having  different structures and 
mechanisms of action. Multidrug resistance (MDR) increases disease 
aggressiveness and significantly reduces survival rates. MDR has been 
associated with multiple alterations including: a) decreased drug accumulation 
due to altered expression of drug trasporters (ABC family); b) increased 
detoxification by Thiols; c) increased tolerance to DNA damage; d) mismatch 
repair deficiency; e) reduced susceptibility to drug induced apoptosis and 
activation of survival pathways (45). Cancer cells can also inherently possesse 
resistance to wide variety of drugs; this is called “Intrinsic Resistance” and is 
potentially due to genetic and epigenetic alternations, such as activation of 
oncogenes and inactivation of tumor suppressor genes. p53  is  a  well  known  
and  extensively  characterized  tumor  suppressor  gene (46).  It  is  the  key 
candidate  in  the  regulation  of  apoptosis  induced  by  various  stimuli.  It is 
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also involved in cell cycle regulation by controlling G1 check point and in 
maintenance of genomic stability. Many anticancer  drugs  exert  their  action  
by  inducing  DNA  damage,  which  in  turn  activates  p53 apoptotic  pathway,  
eventually  leading  to  cell  death.  However, 50% of cancers have defects in 
p53 pathway, due to p53 point mutations or deletions (46). Growing evidences 
suggest association between intrinsic resistance and the presence of cancer stem 
cells  in the tumor  population (47). Cancer stem cells have been shown to 
constitutively express drugs  transporters,  DNA  repair  genes,  and  to be  
resistant  to  apoptosis. Presence of tumor stem cells may therefore provide a 
source for disease recurrence and metastasis. Standard chemotherapy for EOC 
is based on platinum compounds that exert their anticancer effects via multiple 
mechanisms. The most prominent one involves the generation of DNA lesions 
which can be recognized by multiple repair pathways leading to the activation 
of signaling cascade with proapoptotic outcomes that are often impaired in 
resistant cancer cells. My laboratory has contributed in defining the central role 
of p53 status in tumor escape from death receptor apoptotic related 
(48),(49),(50),(51). However, genetic and epigenetic alterations in the 
components of this complex signaling network have been also associated with 
variable levels of resistance to cisplatin (52), (53). 
6 The relationship between cellular metabolism and drug resistance 
Cancer cells posses a unique metabolic profile since they are more dependent 
on aerobic glycolysis, fatty acid synthesis and glutamine metabolism. 
Increasing evidence supports the idea that dysregulated cellular metabolism is 
linked to drug resistance in cancer therapy. Several glycolytic enzymes as 
glucose transporters (GLUTs), hexokinase (HK), pyruvate kinase (PK), lactate 
dehydrogenase A (LDHA) have been found iperexpressed and iperacrivated in 
cancer cells. In different tumor types these alterations are related to drug 
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resistance being involved in repressing pro-apoptotic signaling or activating 
compensatory pathways (54). Also the regulation of oxidative stress is an 
important factor in both tumour development and respons to anticancer 
therapies. Reactive oxygen species (ROS) and tumor biology are intertwined in 
a complex network, making it difficult to understand which came  
first, whether oxidants are required for tumor cell growth or whether oxidant 
stress can be exploited therapeutically. Imbalances of cellular redox state may 
render cells vulnerable to chemotherapeutic agents (55). Many conventional 
antitumor agents have been shown to trigger cancer cell death by inducing 
oxidative stress; therefore, targeting oxidative-stress related pathway is 
considered a promising tool to overcome drug resistance. The major player in 
controlling the intracellular redox balance is reduced Glutathione (GSH) a thiol 
peptide which tightly regulates cell redox status through its antioxidant and 
reducing activities (56). Combining chemotherapeutic agents with targeted 
disruption of dysregulated cellular metabolism represents a promising strategy 
to overcome drug resistance and improve the efficacy of current 
chemotherapeutic agents in cancer patients (57). 
7 Role of glutathione in cancer progression and chemoresistance  
ROS are physiologically produced by aerobic cells and their production 
increases under conditions of cell injury (58). Physiological levels of ROS 
mediate crucial intracellular signaling pathways and are essential for cell 
survival. However, an excess of ROS formation generates cell damage and 
death. To prevent cell damage, the increase of ROS induces an adaptive 
response, consisting in a compensatory up-regulation of antioxidant systems, 
aimed to restore the redox homeostasis. Oxidative stress has long been 
implicated in cancer development and progression suggesting that antioxidant 
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treatment may provide protection from cancer (58). On other hand, pro oxidant 
therapies, including ionizing radiation and chemotherapeutic agents, are widely 
used in clinics, based on the rationale that a further oxidative stimulus added to 
the constitutive oxidative stress in tumor cells should, in fact, cause the collapse 
of the antioxidant systems, leading to cell death (59) . Among the enzymatic 
systems involved in the maintenance of the intracellular redox balance, a main 
role is played by glutathione (GSH) (60) that participates, not only in 
antioxidant defense systems, but also in many metabolic processes (61). 
Elevated GSH levels are observed in various types of tumors, and this makes 
the neoplastic tissues more resistant to chemotherapy (62),(63). Moreover, the 
content of GSH in some tumor cells is typically associated with higher levels of 
GSH-related enzymes, such as -glutamylcysteine ligase (GCL) and  -glutamyl-
transpeptidase (GGT) activities, as well as a higher expression of GSH-
transporting export pumps (58) resulting in tumor cell drug resistance  (64) . 
Three mechanisms have been proposed for the role of GSH in regulating 
cisplatin (DDP) resistance: (i) GSH may serve as a cofactor in facilitating 
Multidrug Resistance Protein (MRP) mediated DDP efflux in mammalian cells; 
(ii) GSH may serve as a redox-regulating cyto-protector based on the 
observations that many DDP-resistant cells over-express GSH and  -GCS; and 
(iii) GSH may function as a copper (Cu) chelator.  Additionally, GSH is 
involved in the control of cell cycle regulation, proliferation and apoptosis (65). 
Changes in GSH levels affect mitochondrial pore permeability, depletion of 
GSH leads to the release of cytochrome c and cell death, thus rendering GSH an 
attractive target that could ameliorate the success of conventional cancer 
therapies (56). Interestingly, glutathione levels are higher in ovarian tumors 
than in healthy ovarian tissue, and increased in patients who are nonresponsive 
to therapeutic intervention (66).   
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Aim of the Project 
ChoKα is considered an important posible therapeutic target in many type of 
cancer, including EOCs. In fact, ChoKα expression and activity have a primary 
role in EOC in sustaining the "cholinic phenotype", defined by aberrantly 
increased PCho levels in tumor cells. ChoKα inhibition in appropriate cellular 
models will help to elucidate the biological and clinical relevance of its 
increased expression and activity. This study is mainly committed to 
investigate: 
a) The functional role of ChoKα in the biology of EOC, knowing that 
ChoKα expression and activation increased during EOC progression. 
Therefore, the goal of this section will be to modulate the ChoKα 
expression by transient and stable silencing and analyze the metabolic 
and biological silencing effects. In particular, we will focus the attention 
on its possible druggability by investigating the mechanisms related to 
drug sensitivity/resistance dependent on Chokα expression.  
b) The prognostic role of Chokα analyzing CHKA genes expression 
according to EOC phenotypes in publicly datasets.  
 
The results of this study will contribute to elucidate the complex network that 
modulates the response to chemoresistance in EOC cells and help to identify 
new players that could be exploited to develop novel therapeutic approaches  
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SECTION 1. CHOLINE KINASE ALPHA SILENCING REGULATES 
CELL AGGRESSIVENESS AND DRUG SENSITIVITY IN EOC.  
Results and Discussion 
1.1 Transient CHKA silencing reduces Chokα expression and PCho 
accumulation. 
In order to evaluate the role of ChoKα in EOC growth and progression, we 
silenced its expression in two EOC cell lines, with well known ChoKα activity 
and expression, INTOV11 and SKOV3 (67). Chokα expression was inhibited, 
as first approach, by specific transient RNA interference. Silencing efficacy was 
evaluated 72h after transfection both at transcript and protein level, obtaining a 
significant reduction of ChoKα mRNA and protein expression ranging from 
60% to 70% in INTOV11 and SKOV3 respectively as compared to their 
relative controls (Figure 1A). A proportional drop in PCho content was 
observed in siCHKA cells, as assessed by MRS profiles, confirming the 
dependence of EOC cholinic phenotype on elevated ChoKα expression and 
activity (Figure 1B). Accordingly, the overall tCho contents also decreased 
(41.4% and 44 % in silenced INTOV11 and SKOV3 cells respectively). GPC 
absolute concentration, although highly variable, was not significantly changed 
by CHKA knock-down. No changes were observed in GPC in CHKA-silenced 
INTOV11 cells compared with their controls. Except for CHKA down 
modulation, none of the genes associated to the biosynthetic Kennedy’s 
Pathway resulted perturbated after transient CHKA silencing. The  analysis of 
Chokβ isoform mRNA expression in CHKA-silenced cells showed that levels 
of CHKB transcript remained unchanged as compared to controls in both EOC 
cell lines (Figure 1C), demonstrating also the  specificity of our siRNA pool for 
α isoform. 
Alterations of choline phospholipid metabolism in ovarian cancer: study of the activity and 
expression of choline kinase as a prognostic value. 
 
25 
 
 
1.2 CHKA silencing inhibits cell proliferation without affecting survival 
signalling pathways. 
ChoKα silencing was accompanied by 35% inhibition of cell growth in both 
cell lines (Figure 2A), a 35-38% reduction in S-phase (proportional to growth 
inhibition) and a slight G1 cell cycle arrest as assessed by BrdU incorporation 
and Propidium Iodide staining (Figure 2B). These biologic effects were evident 
only in EOC cell lines and not in the non-tumoral ovarian I64-hTERT cell line 
in spite of the comparable cellular turnover of the two cellular models and of 
the efficient decrease of ChoKα expression at both mRNA and protein levels 
(Figure 3A and 3B) and cellular PCho drop (Figure 3C) following CHKA 
silencing. Indeed, no significant effects on cell proliferation were observed in 
the non tumoral cell line I64-hTERT (Figure 3D). Our results, in agreement 
with data published in the literature, for other type of non tumoral cells (44), 
further support the concept of ChoKα as the major player in supporting cholinic 
phenotype only in tumor cells (13).  
The effects related to CHKA transient silencing in EOC appeared to have 
perturbation on EOC cell behavior different than that observed in other cellular 
models. In fact, we did not observe a reduction of Akt phosphorylation in a 
PI3K-independent way (68), nor an attenuation of MAPK and PI3K/AKT 
signaling (69) (Figure 4). Furthermore, although cell proliferation was reduced 
in both cell lines after CHKA silencing, neither decrease of cell viability nor 
apoptosis were observed in silenced cells. In this respect, EOC seems to behave 
differently than other tumor types in which targeting ChoK by siRNA 
technology (70),(71) or by pharmacological inhibitors (72),(73) was able to 
induce an apoptotic effects.  
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1.3 Modulation of gene expression profiling associated to CHKA silencing  
Since the biological outcomes observed in siCHKA EOC cell lines were not 
super imposable to features described in other tumor models, we investigated 
alteration of global gene expression profile upon CHKA silencing to possibly 
identify the main pathways affected. By class comparison analysis of 
INTOV11- and SKOV3- CHKA silenced vs. control cells, we identified 476 
differentially expressed genes in CHKA silenced as compared to control cells, 
252 of them being down-regulated. Importantly, apart from CHKA, none of the 
genes associated to the biosynthetic Kennedy’s Pathway resulted perturbed after 
transient CHKA silencing and CHKB gene was not included among the 
modulated genes thus confirming the data obtained by RT-qPCR (see Figure 
1C). 
The 15 genes most consistently up or down regulated following CHKA 
silencing are reported in Table 1. Microarray data were validates by Real time 
PCR or Bioplex analysis for six selected genes (Figure 5 A and B). Among the 
most relevant co-repressed genes we focused our attention on Cyclin A1 
(CCNA1), related to regulation of cell cycle progression and cytokines genes 
(IL6 and IL8) related to inflammation and EOC aggressiveness.  We observed a 
consistent and reproducible decrease of IL6 and IL8 mRNA levels associated to 
a decrease of protein release in conditioned supernatant of siCHKA cells 
(Figure 5C). It is now established that in EOC IL6 and IL8 expression is 
induced by lysophosphatidic acid (LPA) (74), (75),(76) a biolipid that, by 
upregulating these cytokines, stimulates tumor cell invasion and metastasis. 
Interestingly, LPA can be produced by phosphatidic acid (PA), a breakdown of 
PtdCho by PC-PLD, an enzyme involved in the catabolic pathway of PtdCho  
(14),(77). Down-modulation of these cytokine following CHKA silencing 
might be then related to a lower availability of LPA, derived from possibly 
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altered PtdCho turnover. Form a metabolic point of view, among the most up-
regulated genes, we identified as gene of interest Osteoprotegerin 
(TNFRSF11B; OPG), a soluble decoy receptor for receptor activator of nuclear 
factor-kappa B ligand (RANKL); Acyl-CoA synthetase (ASCM3), needed for 
fatty acid synthesis and accumulation of cytoplasmic lipid droplets (78),(42);  
Phosphatidic acid phosphatase 2A (PPAP2A), a biolipid mediator that converts 
phosphatidic acid to diacylglycerol. It has been reported that an increase of 
PPAP2A activity, due to a gene up-modulation, could terminate Raf-1 and the 
MAP-kinase pathway signaling overall affecting cell proliferation (79).  
1.4 CHKA silencing modulates cell functions related to cell movement and 
affects drug sensitivity. 
To derive the possibly deregulated pathways following CHKA silencing, a 
dataset consisting of the 476 differentially expressed genes was analyzed with 
Ingenuity Pathway Analysis (IPA) Tool, revealing 25 significantly altered 
pathways: the network identified with the highest score included CHKA among 
the focus molecules (Figure 6). The biological functions associated to this 
network were related to cell morphology, cellular assembly and organization, 
cellular function and maintenance. The molecular and cellular functions 
affected by CHKA silencing were related to cell death, cellular growth and 
proliferation and cellular movement (Figure 7A). Interestingly, as shown by the 
z-score heatmaps (Figure 7B), Cellular movement and cellular growth and 
proliferation functions were predicted to be decreased whereas cell death 
function was predicted to be increased in CHKA-silenced cells as compared to 
their controls. The predicted alterations of these pathways were supposed to 
lead EOC cells towards a less tumorigenic behavior. 
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Indeed, following CHKA knockdown, a decreased proliferation was evident 
(see Figure 2)  and a clear delay in wound closure was observed in both CHKA-
silencing cell lines using the classic scratch assay (Figure 8A). Since the 
significantly reduced cell motility observed in CHKA silenced cells as 
compared to their control cells could be partially due to a reduced proliferation 
capability, to possibly exclude effects of CHKA silencing related to 
proliferation rather than migration, scratch assay was also performed in the 
presence of Actinomycin D obtaining comparable inhibitory effects. Indeed we 
observed an inhibition of wound repair of 46% in INTOV11 and 45% in 
SKOV3 CHKA-silenced cell lines, thus suggesting that results observed were 
mostly related to alterations of the migratory rather than proliferative phenotype 
(Figure 8B). 
Also, CHKA silenced cells showed a dramatic rearrangement of F-actin fibers 
with a significant reduction of oriented actin stress fibers and focal adhesion 
sites (Figure 9), further suggesting that CHKA silenced cells are less prone to 
movement and migration as compared to their control cells. To confirm these 
indications, we then assessed migration capability by using two assays both 
based on the Boyden chamber principle but having different detection methods 
to account for methodological variability and in presence of Actinomycin D to 
exclude bias related to proliferative effects. Results obtained  showed a 43-47% 
inhibition of migration in INTOV11 and SKOV3 CHKA-silenced cells as 
compared to their relative controls when migration was detected by fluorimetric 
assay; comparable results were obtained when Actinomycin D was added to 
culture medium (Figure 10 A). Also a 37-65% inhibition of migration was 
detected in INTOV11 and SKOV3 cells as compared to their relative controls 
when migration was detected by quantification of SRB staining (Figure 10 B). 
Furthermore, CHKA-silenced cells showed a significantly reduced (72% and 
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79% in silenced INTOV11 and SKOV3 respectively) invasive potential through 
matrigel as compared with their control cells (Figure 11).  
Furthermore, although we did not show any direct effect of ChoKα down-
regulation on cell death, to possibly confirm the IPA-predicted modulation of 
cell death function, we evaluated sensitivity to drug treatments upon CHKA 
silencing. As compared to their relative untreated cells, we observed a 
significant increase of sensitivity to cisplatin (DDP) treatment associated with 
CHKA silencing in both INTOV11 and in the DDP-resistant SKOV3 cell line 
(Figure 12A). Importantly, we observed also a sensitization of the CHKA-
silenced cells to the other two drugs, Paclitaxel and Doxorubicin, that are 
currently in use in the clinical practice for EOC treatment in combination with 
platinum compounds (Figure 12B and C). In agreement with the increased drug 
sensitivity, CCNA1 down-modulation following CHKA silencing might then 
impair the ability of cells to arrest cell cycle to repair DNA following DNA 
damage. CCNA1 is indeed a down-stream target of p53 able to mediate a G2/M 
cell-cycle arrest (80). A cell sensitization to drug treatment (5-fluoruracil) after 
CHKA silencing has been already reported also in breast (81) and colorectal 
cancer cells (38). 
Conclusion and Future Perspectives 
Aberrant choline metabolism, characterized by an increased intracellular PCho 
pooling and sustained by increased activity/expression of ChoKα, is a new 
metabolic hallmark for different cancer types (13). Our previous studies 
significantly contributed to define its relevance also in EOC, showing that 
tumor cells have an increased expression and over activation of its enzyme (14), 
(29). The results collected in this section showed that specific CHKA transient 
silencing induces a decrease of cell proliferation, a reduction of migration and 
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invasion capability and increases sensitivity to drug treatment. These biological 
effects were evident only in EOC cell lines and not in non tumoral ovarian 
cells, suggesting that Chokα sustains the “cholinic phenotype” only in tumor 
cells. When considering the biological relevance of CHKA knockdown it 
should be taken into account that the specific EOC molecular context may 
require longer time and a more persistent CHKA down regulation to achieve a 
more effective modulation of cell behavior. A transient inhibition of CHKA in 
EOC could be not sufficient alone to maintain overtime the biological effect of 
its silencing. Furthermore, in a previous study we also showed that the 
alterations of EOC tCho MRS spectral profile is sustained also by activation of 
enzymes involved in  PtdCho catabolic pathways like PC-PLC  
(14),(31),(29),(32). Therefore a simultaneous inhibition of the enzymes 
involved in both the biosynthetic and the catabolic pathways could be more 
appropriated in these cellular models to obtain a stronger biological effect.  
The increased sensitivity of EOC cell lines to drug treatment when interfering 
with Chokα expression, has an important biological relevance to support the 
concept of targeting metabolism to improve efficacy of existing standard 
chemotherapeutic approaches (82) and opens the way to validate ChoKα as a 
druggable target. 
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SECTION 2. CHOLINE KINASE ALPHA KNOCKDOWN SENSITIZES 
OVARIAN CARCINOMA CELLS TO ANTITUMOR AGENTS BY 
IMPARING GLUTATHIONE DEPENDENT ANTIOXIDANT DEFENSE.  
Results and Discussion 
2.1 Molecular and functional characterization of stable CHKA silencing  
Since the dynamics of biological effects related to CHKA silencing could differ 
from other cancer types and could not possibly be detectable by transient RNAi, 
we stably downregulated ChoKα expression using a lentiviral vector, 
expressing GFP and specific ChoK shRNA (Figure 13 A). Stable CHKA 
silencing caused: i) reduction of CHKA-mRNA (61% and 68% for INTOV11 
and SKOV3 respectively as compared to their relative control (Figure 13B), ii) 
down modulation of ChoKα protein expression (40% and 41% for INTOV11 
and SKOV3 transduced cell lines, respectively) (Figure 13C), iii) a significant 
drop of PCho content in silenced cells (Figure 13D).  
The indirect evidence of decreased ChoKα activity (evaluated as decrease of 
PCho content) in sh-CHKA cells was confirmed by the direct measurement of 
enzymatic activity in both EOC models. Indeed, consistently with the reduction 
of PCho levels in sh-CHKA transduced cells a significant decrease of 77% and 
97% of ChoK enzymatic activity as compaired to controls was detected both for 
INTOV11 and SKOV3 cell lines (Figure 13E). We clearly showed that the 
depletion of CHKA expression was associated to a drop in PCho content and 
CHK activity, indicating in these EOC cells a predominant role of the alpha 
isoform in the build-up of PCho in these cancer cells. Furthermore, we did not 
observe any significant changes in the levels of PtdCho in CHKA-silenced 
cells, suggesting that the phospholipid homeostasis was not substantially altered 
under these experimental conditions. A 44.4% and 49.63% in vitro growth 
Anna Granata 
32 
 
inhibition was obtained for sh-CHKA INTOV11 and sh-CHKA SKOV3 
respectively as compared to their relative controls (Figure 14 A). With the 
stable transfection approach we were able to assess the inhibition of foci 
formation: 10 days after cell seeding, the INTOV11 and SKOV3 sh-CHKA 
cells showed a 38% and a 61.6% reduction in colony formation (Figure 14B). 
We also confirmed in sh-CHKA transduced cells a 40% and 51% reduction of 
migration capability (Figure 14C) and 41% and 45%  inhibition of invasive 
potential (Figure 14D) compared with their control cells, in INTOV11 and 
SKOV3 models, respectively.  
2.2 CHKA stable silencing inhibits EOC xenotraplants growth 
Given the strong inhibitory effects on in vitro cell proliferation by CHKA stable 
silencing, we evaluated potential inhibitory effects in in vivo experiments. Nude 
mice were injected subcutaneously with 3x10^6 sh-CHKA or control cells 
(ΔLuc). Tumor volumes were monitored and a significant inhibition of tumor 
growth was observed for both EOC silenced cell lines (Figure 15 A). Tumors 
derived from control and CHKA silenced xenografts were analyzed at 
molecular and enzymatic level. RTqPCR (Figure 15B) confirmed the stable 
CHKA downmodulation. The decrease of PCho accumulation is evident in the 
CHKA-shRNA transduced tumors (Figure 15C). The percentage of reduction of 
PCho accumulation has reached 60% in both models.  
Our results showed that CHKA stable silencing significantly affected EOC in 
vivo growth supporting the hypothesis that EOC aggressiveness could be due, at 
least in part, also on the expression and activity of this enzyme. In spite of 
safety concerns involving use of lentivirus as a mode of gene delivery, these 
studies, conducted in breast and ovary, may be the bases for future gene therapy 
trials targeting Chokα in tumors. Indeed, our collaborators using the same 
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approach, demonstrated for the first time, the therapeutic potential of CHKA 
down regulation in vivo in a human breast cancer xenograft model (43). 
2.3 Metabolic impact of CHKA silencing 
Global biochemical profiles, performed with the Metabolon technology 
platforms, were determined comparing ΔLuc and sh-CHKA cells for INTOV11 
and SKOV3 EOC models collected 24 and 72 hours after plating. The first 
evidence from metabolic profile was the distinct separation between the two 
cell lines consistent with fundamental metabolic difference between the two 
phenotypically different cell lines. The greatest metabolic changes were 
observed 72h post seeding where a number of metabolites were found to be 
down-regulated in CHKA silenced cells (Table 2). The complete heatmap of 
significantly altered metabolites for each cell line is reported in Table 3 We 
identified as commonly altered in the two sh-CHKA models, metabolic 
pathways mainly related to amino acid, lipid and nucleotide metabolism (Table 
4). We found of particular interest the altered glutathione metabolism 
characterized by decreased content of glutathione and its precursor cysteine. 
Indeed, in both cellular models, CHKA stable silencing resulted in a significant 
decrease in cysteine levels as compared to the relative controls (ΔLuc) (Figure 
16A), coupled with an alteration of glutathione metabolism, commonly 
characterized by a 3-fold decrease of reduced glutathione (GSH) and a 2-fold 
decrease of oxidized glutathione (GSSG) content (Figure 16B). A 30-40% 
reduction of GSH/GSSG ratio indicated an overall decrease in GSH content in 
sh-CHKA cells as compared to their controls (Figure 16C). To independently 
validate this observation, we transiently silenced CHKA expression on 
INTOV11 and SKOV3 and quantified GSH and GSSG levels using the 
luminescence-based system GSH/GSSG-Glo assay, obtaining a 2 fold reduction 
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of GSH/GSSG ratio in silenced (si-CHKA) cells compared to their relative 
controls (Figure 16D). To verify whether an altered expression of the cysteine 
transporter (Sxc) could account for the decrease in cysteine observed in sh-
CHKA cells, we analyzed the expression of the transporter subunit xCT both at 
mRNA and protein level, but we did not observe any alteration following 
CHKA silencing thus excluding a decrease in cysteine uptake (Figure 17). 
Further analysis will be performed to assess whether CHKA silencing impact 
on expression of enzymes involved in trans-sulfuration pathway or enzymes 
involved in glutathione synthesis. 
To exclude that this metabolic change was a cell line-dependent effect but was 
extensible to other EOC cellular models, CHKA was silenced in four different 
EOC cell lines, IGROV1, A2774, OAW42 and OVCAR5, with heterogeneous 
ChoKα protein expression levels and PCho intracellular accumulation (Figure 
18  A and B). In all tested cell lines, CHKA transient silencing induced an 
average 60% decrease of ChoKα protein expression (Figure 18 C) and a 
significant 2 fold decrease of the GSH/GSSG ratio (Figure 18 D). To exclude a 
non specific off target effects, GSH decrease after CHKA silencing was 
validated also with an independent CHKA specific siRNA pool (Figure 18E).  
2.4 CHKA silencing by modulating intracellular GSH levels affects cell 
sensitivity to drugs. 
The mechanisms of cytotoxic drug resistance in EOC remained unclear. Among 
the various mechanisms, high intracellular GSH levels have been shown to 
contribute in developing resistance to chemotherapeutic drugs including DDP 
and doxorubicin, two drugs targeting DNA. Consistently, increased GSH 
contents has been observed in different tumour types and a relationship with 
resistance to a number of drugs has been described (56). GSH acts as scavenger 
of free radicals and peroxides accumulating in the cell during oxidative stress 
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like the hypoxic condition in tumour tissues, where GSH plays a protective role. 
Therefore, treatments causing GSH depletion are expected to render cancer 
cells more susceptible to chemotherapeutic agents, while sparing normal cells. 
GSH is well known to regulate redox state through its antioxidant and reducing 
activities. Our observations suggested that CHKA knocking down, by altering 
GSH intracellular levels, may cause an increase in ROS levels thus impairing 
antioxidant cellular defense and possibly response to drug treatment. Indeed, we 
assessed the ROS intracellular levels measuring by flow cytometry the CM-
H2DCF-DA probe fluorescent signal in control and si-CHKA cells. A 3-fold 
and a 6-fold increase in intracellular ROS levels was detected in INTOV11 and 
in SKOV3 siCHKA cells respectively as compared to their corresponding 
controls (Figure 19).  Interestingly, as I reported in Section 1 of my results, 
CHKA silencing in INTOV11 and SKOV3 increased sensitivity to DDP and 
doxorubicin treatment (see Figure 12) and this effect was reproducible in four 
additional EOC cell lines following CHKA down modulation (Figure 20). 
We therefore investigated whether the alteration of GSH/GSSG levels 
dependent upon CHKA silencing was the mechanism by which cell sensitivity 
was modulated. Thus, to phenocopy the effects of CHKA-silencing, we reduced 
basal intracellular glutathione levels treating wild type INTOV11 and SKOV3 
cells with a non toxic concentration of Buthionine Sulphoximine (BSO), a well 
known inhibitor of gamma-glutamylcysteine synthetase. As hypothesized, this 
GSH-depleting agent significantly increases DDP and doxorubicin sensitivity 
mimicking the pattern of sensitization observed after CHKA silencing (Figure 
21). As complementary approach, we examined if we could rescue the resistant 
phenotype in INTOV11 and SKOV3 siCHKA cells restoring GSH intracellular 
levels. The glutathione tripeptide itself is not cell permeable, therefore to 
increase its intracellular content we loaded cells with a membrane/lipid 
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permeable derivative, Glutathione Reduced Ethyl Ester (GEE) and we 
evaluated the capability of GEE treatment to recover intracellular GSH levels in 
siCHKA cells. After CHKA silencing, cells were loaded with 10µM GEE for 
8h and then incubated for 48h in the absence of this agent, resembling the time-
schedule of the drug treatment. GSH/GSSG levels were monitored and 
quantified at the end of silencing (t0), after loading (8h GEE) and at the end of 
experiments. CHKA silencing caused in both cell lines the expected 2-fold 
decrease of GSH/GSSG ratio as compared to relative controls (Figure 22, t=0). 
We observed that GEE treatment effectively recovered GSH levels in both 
siCHKA cell lines (Figure 22 A, green histograms) and such an increase was 
maintained up to 48h after the end of GEE loading. Most importantly GSH 
reloading in siCHKA cells substantially affected intracellular ROS levels, by 
lowering their amount to levels comparable to drug treated control cells (Figure 
22 B) . Significantly, GEE treatment reverted drug sensitization associated with 
CHKA silencing, almost completely retrieving the dose-response curve typical 
of wt and control cells (Figure 22C).  
2.5 CHKA silencing does not affect Glutathione metabolism and/or drug 
sensitivity in non - tumoral ovarian cells. 
As I reported in the first section of results, the biological effects of CHKA 
silencing were evident only in cancer cells. Interestingly, GSH levels have been 
reported to be higher in ovarian tumors that in normal ovarian tissue (66),(83). 
Thus, to assess the specific biological impact of GSH regulation by CHKA 
expression in EOC cell lines, we evaluated the GSH/GSSG ratio in the non-
tumoral ovarian cell line I64-hTERT and its possible alteration following 
CHKA silencing. 
The GSH/GSSG ratio was significantly higher in EOC cells than in I64-hTERT 
(Figure 23A) and knock-down of CHKA did not impact on GSH intracellular 
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levels (Figure 23B) and drug sensitivity of I64-hTERT cells (Figure 23C). GSH 
depletion by BSO resulted in a sensitization of I64-hTERT cells to DDP but no 
differences were detected between silenced and non silenced cells (Figure 24A 
and B). Indeed, GEE treatment caused a moderate increase in the GSH levels in 
I64-hTERT (Figure 24C), and accordingly no differences were observed in drug 
sensitivity of siCHKA, GEE-treated cells (Figure 24D).  
Conclusion and Future Perspectives 
The results reported in this section demonstrated that stable silencing of CHKA 
in two different EOC cell lines reduced in vitro cell proliferation, migration and 
invasion capability and affected EOC in vivo growth supporting the hypothesis 
that EOC aggressiveness could be due in part to iper expression and over 
activation of this enzyme. In fact, following CHKA knocking down the cells 
showed a less aggressive phenotype.  
On the other hand, the analysis of global metabolic profiling identified an 
altered glutathione metabolism characterized by a decreased cysteine and GSH 
content. The reduction of GSH content is expected to perturb redox homeostasis 
in EOC cells and renders tumor cells more susceptible to chemotherapeutic 
treatment. Accordingly, we observed that CHKA targeting, either by shRNA as 
well as siRNA, increased ROS intracellular levels and sensitivity to cisplatinum 
and doxorubicin treatment and these effects were mediated by the reduction of 
GSH content,  even in drug resistant EOC model. Interestingly, alteration of 
GSH levels and increased sensitivity to drug treatment were found in different 
EOC cellular models, despite the different Chokα expression, but not in non 
tumoral EOC cells. Targeting mechanisms upon which cancer cells are 
expected to be dependent (CHKA expression and cellular ROS homeostasis) 
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could explain the differential response of cancer and non transformed cells to 
CHKA knock-down. 
As well known, cancer cells acquire specific genetic and epigenetic alterations 
that involves hyperactivation of oncogenes and/or inactivation of 
oncosuppressor genes. Some genetic changes support survival of cancer cells 
by creating specific signalling sustaining metabolic pathways. However, the 
overall deregulation of cellular processes and functions is frequently associated 
with enhanced cellular stress and malignant cells have to adapt to this 
phenotype, becoming dependent on a number of non-oncogenic functions to 
survive (84). Similarly, a dependency associated with ROS homeostasis has 
been shown to constitute a selective liability of malignant cells also in xenograft 
tumor models (85). Identifying such dependencies represent a promising 
alternative for the development of new therapeutic strategies to successfully 
target metabolic enzymes minimizing adverse effects on normal tissues. 
Synergisms of CHKA knockdown with conventional treatment might open 
interesting clinical perspective as it could represent an alternative strategy to 
increase the treatment efficacy also by reducing the clinical dose of drugs and 
limiting the damage of normal cells. 
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SECTION 3. EVALUATION OF PROGNOSTIC ROLE OF CHOLINE 
CHINASE ALPHA IN EOC: BIOINFORMATICS ANALYSIS. 
Results and Discussion  
The over expression of ChoKα in many cancer types has also generated interest 
in phospholipid metabolism as a diagnostic or therapeutic target in oncology 
(13),(28). ChoKα over-expression has been reported and proposed as an 
indicator of reduced patient survival in human lung and bladder carcinomas 
(35),(86).  
My group in past years analyzed, for the first time in EOC, the CHKA mRNA 
expression in EOC surgical specimens (29). Gene expression analyses were 
performed on 21 frozen EOC surgical specimens, 2 OSE cells preparation and 8 
different EOC cell lines. The mRNA relative expression levels of ChoKα 
measured in clinical tissue samples were significantly higher than those in OSE 
cells (Figure 25A) overall these expression levels were however lower than 
those detected in EOC cell lines. The different gene expression levels of ChoKα 
between tumor samples and cell lines may derive from stromal contamination 
and/or from in vitro culture conditions. The increased although heterogeneous 
expression of ChoKα was also confirmed at protein level by Western blot 
analysis of lysates of surgical specimens randomly selected from those analyzed 
for gene expression (Figure 25 B).  
In order to investigate the putative prognostic role of CHKA in EOC we 
performed a preliminary in silico analysis on available public data sets of gene 
expression profiling of EOC tumors (see Table 5 for detailed description). We 
firstly performed a metanalysis of metabolism-related genes expression in high 
grade serous EOC compared to OSE cells. To this end we selected a total of 
119 genes involved in KEGG hs-glycerophospholipid pathway (hsa:00564) or 
reported to be directly involved in Kennedy’s pathway ((87)), and we compared 
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their expression profile between OSE and tumor samples on a joined dataset 
derived from Bowen, Mok and Bonome dataset. (88),(89), (90). Complete 
heatmap is reported in Figure 26. 96 out of the 119 metabolism-related genes 
were identified in the dataset and 71 of these genes resulted differentially 
expressed (FDR <0.06) between the two groups (OSE cells vs EOC tumors). 
Interestingly, OSE cells showed a higher CHKB expression as compared to 
EOC samples, whereas CHKA expression was higher in tumors respect to OSE 
cells (Figure 26). We then analyzed the expression profile of this selected gene-
set in the Anglesio dataset (91) that comprise Low malignant potential (LMP) 
and Malignant tumors. LMP serous EOCs are thought to arise by the 
transformation of tumors of borderline malignancy and activating mutations in 
members of RAS pathway (KRAS, BRAF, ERB2) are found in the majority of 
these tumors (92). LMP EOCs show a relatively high grow capacity, are usually 
not invasive but resistant to conventional chemotherapy (93). With this analysis 
we identified a cluster of genes overexpressed in LMP and one overexpressed 
in malignant tumors (Figure 27A). CHKA and CHKB were among the 
differentially expressed genes between the two groups and whereas CHKB 
showed higher expression in LMP EOCs, CHKA was overexpressed in 
malignant EOCs (Figure 27B). Of note, this finding was further confirmed 
when we analyzed the Tothill dataset (94) that includes a higher number of 
patients comprising LMP, Malignant type I and malignant type II tumors. By 
this analysis we found 111 metabolism-related genes present on the array, 42 of 
which were significantly differentially expressed (FDR<0.05) (Figure 27 C). 
Interestingly, CHKA and CHKB were among them and maintained the same 
expression pattern as above described (see arrows in the heatmap of Figure 27 
C). 
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Given these data, we hypothesized that increased CHKA expression could be 
associated with increased tumor aggressiveness. We therefore analyzed the 
expression of the two enzyme isoforms in 3 datasets King (95), Berchuck (96) 
and Tothill (94) which included malignant tumors of different grading. In 
accordance with our hypothesis, we observed a general increase of CHKA 
expression with tumor grading in all datasets whereas CHKB expression 
showed an opposite trend (Figure 28). 
Conclusion and future perspectives  
By applying these preliminary bioinformatics analysis, we firstly validated that 
CHKA is over expressed in tumor samples compared to OSE cells, whereas 
CHKB in the same samples showed an opposite trend. Moreover, we found a 
progressive increase of CHKA expression along with tumor aggressiveness 
although the number of samples analyzed was limited by the availability of 
datasets including OSE cells, LPM and malignant EOC tumors.  
For the future we plan to: i) confirm these results performing further analysis in 
newly collected case materials; ii) validate the prognostic relevance of CHKA 
and CHKB expression performing survival analysis; iii) investigate the putative 
causal relationships at the basis of the complex network of interactions between 
CHKA-CHKB and metabolism related genes. 
  
Anna Granata 
42 
 
FIGURES AND TABLES 
  
Alterations of choline phospholipid metabolism in ovarian cancer: study of the activity and 
expression of choline kinase as a prognostic value. 
 
43 
 
 
 
 
Figure 1. Transient CHKA-silencing efficiently down-modulates ChoKα expression and 
intracellular PCho content in EOC cell lines.   
A: CHKA silencing was confirmed at mRNA (RT-qPCR, upper panel; data are the mean±SD of 
5 independent experiments) and protein expression level (lower panel: Western Blotting of a 
representative experiment is reported). B: Representative examples of alterations induced by si-
CHKA on the 1H-MRS tCho profile and its PCho component. Black lines: control cells; grey 
lines: silenced cells. Inset in lower panel: western blot of control and si-CHKA EOC cells 
probed with specific antibody to ChoKα. GPC, glycerophosphocholine; PCho, phosphocholine; 
tCho, total choline-containing compounds. The PCho/tCho ratio was 0.75±0.20 in both cell 
types before silencing. C: RT-qPCR for ChoK β-isoform. Data are the mean±SD of 5 
independent experiments. GAPDH was amplified as endogenous control and I64-hTERT cells 
preparations were used as calibrator. 
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Figure 2: Cell proliferation upon CHKA silencing  
A: Proliferation curves. Viable cells were counted 24, 48 and 72h post-transfection. Cells were 
seeded in triplicates at 1 × 105 /well on 12-well plates. After transfection, proliferation was 
assessed at each time-point by Trypan Blue exclusion assay using Countess automated cell 
counter. Cell viability was evaluated as percentage of alive cells in the total cell population. 
Mean percentage of growth inhibition of CHKA-silenced vs. control cells is reported below.     
B: Representative experiment of BrdU incorporation 72h after transfection. Cells were pulsed 
with 10 μM 5’-bromo-2’-deoxyuridine (BrdU) for 1 hour at 37°C, harvested and serially 
washed in PBS. Following fixing with 70% ethanol, cells were processed using BrdU Labelling 
and detection kit according to manufacturer’s protocol. Samples were double-stained by 
incubation with 5 μg/ml Propidium Iodide and 0.5 mg/ml RNAse for 30 min, then they were 
analyzed with FACS Canto and the data processed using FlowJo 7.6.4 Analysis Software.  
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Figure 3. Effects of CHKA downmodulation in non tumoral  I64-hTERT cells.  
A: RT-qPCR for CHKA expression on silenced and control cells. GAPDH was amplified as 
endogenous control and I64-hTERT wild type cells were used as calibrator. B. Upper panel: 
Representative Western blotting analysis of ChoKα expression on silenced and control cells.  β-
actin protein levels were used as loading control. Lower panel: Densitometric analysis of 
ChoKα protein levels normalized to β-actin. Relative percentage of ChoKα protein expression 
is shown respective to control cells set to 100%. C: Quantification of PCho intracellular 
concentrations obtained from 1HMRS spectra of water-soluble cell extracts. D: Proliferation 
curves of control and CHKA-silenced cells. Viable cells were counted 24, 48 and 72 h after 
transfection. Mean percentage of growth of CHKA-silenced vs. control cells is reported below.  
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Figure 4: Effects of CHKA silencing on survival pathways activation. 
Western blots of the time course of CHKA knockdown in INTOV11 and SKOV3 cells. β-actin 
is shown as a control for protein loading. A representative experiment of 3 performed is shown.  
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Gene Symbol
Parametric 
p-value
FDR
a
Geometric 
mean of 
intensities
b
 
CHKA 4,60E-06 0,0421 0,44
CCNA1 2,60E-06 0,0421 0,48
KRT80 0,0005081 0,128 0,51
IL6 0,0046555 0,213 0,51
TAGLN 0,0064673 0,236 0,53
IL8 9,30E-06 0,0467 0,54
AKAP12 0,0009146 0,145 0,56
H19 3,29E-05 0,106 0,59
IDH2 5,34E-05 0,106 0,59
TNFRSF25 0,0011795 0,148 0,61
KRT7 0,0016046 0,163 0,61
LIMK1 0,0054187 0,222 0,61
MAD2L1 8,14E-05 0,124 0,62
SEC23A 0,0001111 0,124 0,62
SNX25 0,0007806 0,137 0,62
ARFIP1 0,0009437 0,146 1,57
CA5B 0,0022191 0,169 1,57
LAMC1 0,0002072 0,124 1,59
C5 0,0013041 0,155 1,6
PRSS35 0,0004709 0,128 1,62
SPTLC3 0,0002098 0,124 1,63
UBE2E3 4,63E-05 0,106 1,64
BCMO1 0,0001368 0,124 1,64
ID3 0,0032983 0,19 1,67
PPAP2A 0,0001578 0,124 1,71
LRRC31 0,0001612 0,124 1,72
RTN4 3,78E-05 0,106 1,76
FXYD2 0,0025975 0,175 1,84
TNFRSF11B 0,0001958 0,124 1,85
ACSM3 4,54E-05 0,106 2,11
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Table 1. List of the  top 15 differentially up or down regulated genes 
following  CHKA silencing
a
: False Discovery Rate (FDR); 
b
: for each specified probe represents the 
ratio between the mean intensity of the  siCHKA vs. control cells
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: List of the top 15 differentially up or downregulated genes following CHKA silencing 
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Figure 5: Validation of genes perturbed by CHKA silencing 
RT-qPCR of selected up (A) and down (B) modulated genes in CHKA-silenced EOC cell lines. 
GAPDH was amplified as endogenous control and I64-hTERT cells preparations were used as 
calibrator. The mean of five independent experiments is reported. C) Evaluation of IL6 and IL8 
release by bioplex assay on conditioned media from both EOC cell lines. Data are the mean±SD 
of 3 independent experiments. 
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Figure 6: Graphical representation of the most highly rated network as obtained by 
Ingenuity Pathway Analysis (IPA).  
The defined statistically significant genes are shaded and the intensity of the shading shows the 
degree of relative modulation. Red and green shading are for up- or down-regulated genes in 
CHKA-silenced cells. A solid line represents a direct interaction between the two gene products 
and a dotted line means there is an indirect interaction. All molecules participating to the 
network are listed below. The focus molecules of the network significantly affected by CHKA 
silencing are reported in red or green color, depending on their relative modulation as above 
described.  
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Figure 7. Prediction of cellular functions affected by CHKA silencing.  
A: List of the cellular functions significantly affected by CHKA silencing by IPA analysis. For 
each of them the number of related molecules significantly altered upon CHK downregulation 
and their level (range) of significance is reported. B: Detailed z-score heatmap of the three most 
relevant altered cellular functions predicting their relative alteration in CHKA-silenced cells as 
compared to control. Square in the heatmap are divided in hierarchical levels from high-level 
functional category (listed in the bar) to mid level sub-functional categories and specific 
functions. Blue and orange shading represent a prediction of decrease or increase of the 
specified function, and the intensity of the shading indicates the prediction strength. The size of 
squares reflects the –log of the calculated P value, with larger square indicating more significant 
overlap between dataset observations and predicted function. 
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Figure 8. CHKA silencing regulates cell migration 
A: Wound healing assay: photographs of a representative experiment of three performed taken 
at the time of scratch (t=0) and at t=72h. Magnification 200x; Mean percentage ± SD of 
migration at t=72h is reported in the graph for each cell line. B: mean percentage ± SD of 
inhibition of migration of silenced cells compared to control cells (100%) in absence or 
presence of Actinomycin D (ACTD) for both EOC cell lines is reported.  
  
Anna Granata 
52 
 
 
 
Figure 9. CHKA silencing induces alteration in F-actin organization 
Representative immunofluorescence staining of INTOV11 and SKOV3 CHKA-silenced and 
control cells. Cells were wounded 72h after transfection and analyzed 24h later. F-actin 
filaments were visualized as green fluorescence through Alexa488–phalloidin binding, and cell 
nuclei were stained by DAPI. Actin stress fibers and focal adhesion sites are indicated by red 
arrows (Magnification: 300x). In each panel a picture of the wound border is reported in the 
inset (Magnification 200x).  
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Figure 10. CHKA silenced cells display reduced motility  
Cells migration capability was assessed using two assays both based on the Boyden chamber 
principle but having different detection methods: by relative fluorescence units (RFU) of 
CyQUANT dye binding by cellular nucleic acids in the lysates (left panel) or Odyssey Infrared 
laser scanner quantification after SRB staining (right panel). The fluorimetric assay was 
performed also in presence of Actinomycin D (ACTD) : mean percentage ± SD of inhibition of 
migration of silenced cells compared to control cells (100%) in absence or presence of 
Actinomycin D (ACTD) for both EOC cell lines is reported. 
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Figure 11. CHKA silenced cells display reduced invasion capability 
Photographs of a representative experiment of the matrigel-coated membrane invading cells 
(Magnification 200X).Mean relative percentage ± SD of invasion capability calculated respect 
to control cells set to 100%.  
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Figure 12. CHKA silencing induces sensitivity to drug treatment 
Citotoxicity assay. Sensitivity to: (A) cisplatinum (DDP, from 1x10-4 to 3x10-7 M); (B) 
Doxorubicin (from 1x10-4 to 1x10-7 M); (C)  Paclitaxel (from 2.5µM to 0.016 nM) was tested. 
Mean ± SD of growth percentage of treated vs. untreated cells is reported.  
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Figure 13: Molecular and functional characterization of CHKA stable transduced cells 
A:  structure  of  the  lentiviral vector (Modified from: Krishnamachary et al Cancer Res, 2009). 
B: assessment  of  ChoKα  mRNA  and C:protein  expression  level  in control and sh-CHKA 
transduced  cells. D: Representative MRS  spectra  profile of the  respective  cell  lines. E: 
Chokα enzymatic activity for both cell lines  
  
From: Krishnamachary et al Cancer Res, 2009)
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Figure 14: Biological characterization of CHKA stable silenced EOC cells. 
A: Proliferation curves. Viable cells were counted 24, 48 and 72h post-seeding. Mean ± SD for  
three independent experiments of sh-CHKA transduced cells  vs. control cells (cells transduced 
with ΔLuc-sh-RNA) is reported. B: Representative images of colony formation assay and 
related quantification. Lower panel: the bar graphs show the quantification of the number of 
colonies after 10 days of growth. Data are the mean ± SD of three independent experiments. C: 
Migration assay. Cells migrating through the membrane were measured by relative fluorescence 
units (RFU) of CyQUANT dye binding by cellular nucleic acids in the lysates. The percentage 
of inhibition of migration in sh-CHKA transduced INTOV11 and SKOV3 cells as compared to 
their relative controls (ΔLuc-sh-RNA) is reported. D: Invasion assay. Invasion capability was 
calculated respect to control transduced (ΔLuc-sh-RNA) cells set to 100%. Mean relative 
percentage ± SD of 3 independent experiments is reported 
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Figure 15: Effects of CHKA stable silencing in  EOC xenotraplants 
A: in vivo tumor growth of both transduced EOC cells. 3x106 cells were injected sub-
cutaneously into Nude mice. 5 animals per group (control and sh-CHKA) were treated. B: qRT-
PCR for CHKA mRNA expression of tumors derived from INTOV11 and SKOV3 xenografts. 
Data are the mean ± SD of 5 tumors. GAPDH was used as endogenous control and the I64-
hTERT cell preparations were used as calibrator. C: Representative expanded regions of 1H-
MR spectra from INTOV11 and SKOV3 xenografts. Black lines: cells transduced with ΔLuc-
sh-RNA; grey lines: cells transduced with CHKA-sh-RNA. 
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Table 2: summary of biochemicals that differed significantly between experimental groups 
(control Δluc and stably silenced sh-CHKA) within each cell line 72h after plating.  A summary 
of the numbers of biochemicals that achieved statistical significance (p≤0.05), as well as those 
approaching significance (0.05<p<0.10), is shown; downregulated metabolites are in green, 
upregulated are in red. 
  
Summary Statistics 
ANOVA
Total biochemicals
p≤0.05
Biochemicals
Total biochemicals  
0.05<p<0.10
Biochemicals
Contrasts            
shRNA / Mock
(↑↓) (↑↓)
INTOV11 89 8|81 29 2|20
SKOV3 32 0|32 29 0|29
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Table 3: Heatmap of the metabolites significantly altered in shCHKA INTOV11 and SKOV3 
cell lines as compared to their controls. Downregulated biochemicals with statistical 
significance p≤0.05 are in dark green those approaching significance (0.05<p<0.10) are 
reported in light green. The same criteria are applied for up-regulated biochemicals, which are 
respectively in dark and light red. 
  
Super Pathway
Sub 
Pathway
SKOV3 INTOV11
Amino acid
Peptide
Carbohydrate
Energy
Lipid
Nucleotide
Cofactors and vitamins
Xenobiotics
cysteine, methionine, 
SAM, taurine metabolism
glutathione metabolism
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Table 4: Major metabolic pathways (Super pathway) altered following CHKA stable silencing  
  
Peptide
Dipeptide
gamma-glutamyl
C
ar
b
o
h
yd
ra
te Aminosugars metabolism
Fructose, mannose, galactose, starch, and sucrose metabolism
Glycolysis, g luconeogenesis, pyruvate metabolism
Nucleotide sugars, pentose metabolism
Nucleotide sugars
Energy
Krebs cycle
Oxidative phosphorylation
Li
p
id
Essential fatty acid
Medium chain fatty acid
Long chain fatty acid
Fatty acid, dicarboxylate
Fatty acid metabolism (also BCAA metabolism)
Fatty acid metabolism
Carnitine metabolism
Bile acid metabolism
Glycerolipid metabolism
Inositol metabolism
Ketone bodies
Lysolipid
Sphingolipid
Stero l/Steroid
Super 
Pathway
Sub Pathway
A
m
in
o
 a
ci
d
Glycine, serine and threonine metabolism
Alanine and aspartate metabolism
Glutamate metabolism
Histidine metabolism
Lysine metabolism
Phenylalanine & tyrosine metabolism
Tryptophan metabolism
Valine, leucine and isoleucine metabolism
Cysteine, methionine, SAM, taurine metabolism
Urea cycle; arginine-, proline-, metabolism
Creatine metabolism
Butanoate metabolism
Polyamine metabolism
Guanidino and acetamido metabolism
Glutathione metabolism
Super 
Pathway
Sub Pathway
N
u
cl
e
o
ti
d
e
Purine metabolism, (hypo)xanthine/inosine containing
Purine metabolism, adenine containing
Purine metabolism, guanine containing
Purine metabolism, urate metabolism
Pyrimidine metabolism, cytidine containing
Pyrimidine metabolism, orotate containing
Pyrimidine metabolism, uracil containing
Purine and pyrimidine metabolism
C
o
fa
ct
o
rs
 a
n
d
 
v
it
am
in
s
Biotin metabolism
Fo late metabolism
Nicotinate and nicotinamide metabolism
Pantothenate and CoA metabolism
Pyridoxal metabolism
Riboflavin metabolism
Thiamine metabolism
Vitamin B6 metabolism
X
e
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Figure 16: Effects of stable and transient CHKA silencing on cellular metabolism  
Quantification of metabolic signals of control (ΔLuc) and sh-CHKA EOC cell lines: (A) 
Cysteine; (B left columns) GSSG; (B right columns) GSH signals. Data are mean ± SD of 
values obtained by mass spectrometry (Metabolon Technology) on 4 replicates analyzed 72h 
post seeding. C: GSH/GSSG ratio derived from Metabolon data. D: Validation of GSH and 
GSSG signals variations in transiently CHKA-silenced EOC cell lines using a luminescence-
based assay.  
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Figure 17: Analysis of xCT expression.  
(A-C) Western Blot and (B-D) mRNA analysis of xCT expression in INTOV11and SKOV3 
cell lines stably (A,B) or transiently (C,D) silenced for CHKA expression. 
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Figure 18: Alteration of GSH metabolism following CHKA silencing is a common feature 
of EOC cells.  
Representative experiments in a panel of four EOC cell lines are shown:  A: Immunoblot for 
CHKA protein expression. B: MRS spectra profile for PCho intracellular pooling C: 
Assessment of ChoKα downmodulation by Western blot analysis. β-actin was used as loading 
control. D: Quantification of GSH and GSSG concentration by luminescence-based assay in 
control and siCHKA-EOC cell lines. Data are mean ± SD of 3 independent experiments. 
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Figure 19: CHKA silencing regulates ROS activation. 
ROS levels were measured by flow cytometry using the oxidation-sensitive probe CM-H2DCF-
DA whose fluorescent signal intensity is directly proportional to production of reactive 
oxidants. To calculate the relative fold change of siCHKA signal vs control cells, the cells alone 
without fluorescent dye were used as negative control to derive the mean fluorescence index for 
each sample. A: Relative increase in intracellular ROS levels in si-CHKA silenced cells as 
compared to their controls. B: A representative experiment for each cell line is reported. 
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Figure 20: Increase of drug sensitivity upon CHKA silencing is a common feature of EOC 
cells. Sensitivity to DDP and Doxorubicin treatment were tested in a panel of EOC cell lines 
after CHKA transient silencing (siCHKA). 
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Figure 21: Sensitivity to drug treatment following exposure with BSO. 
Sensitivity to  DDP (upper panels) and doxorubicin (lower panels) in the presence or absence of 
100 μM BSO in wild type INTOV11 and SKOV3 cells. 
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Figure 22: ROS levels and drug sensitivity are affected by modulations of intracellular 
GSH content mimicking CHKA silencing and/or expression. 
A: Reloading of GSH content in siCHKA cells by 10mM GEE treatment. Intracellular levels of 
reduced and oxidized glutathione were monitored at the end of 72h of silencing, after GEE 
loading and relapse. B. GEE treatment decreases ROS levels in siCHKA- drug treated cells. 
Cells were treated with 10µM DDP or doxorubicin in presence or absence of GEE. Control (si-
ctrl) drug-treated cells were used as negative control to measure the specific ROS level 
variation.   
A
0
5
10
15
ctrl nt
siCHKA nt
siCHKA+GEE
 G
S
H
/G
S
S
G
 r
a
ti
o
0
5
10
15
ctrl nt
siCHKA nt
siCHKA+ GEE
 G
S
H
/G
S
S
G
 r
a
ti
o
- +                - +    +         - +     + siCHKA
8h GEE 8h GEE +
48h relapse
INTOV11 SKOV3
GEE
t 0
- - - - +         - - + - +                - +    +         - +     + siCHKA
8h GEE 8h GEE +
48h relapse
GEE
t 0
- - - - +         - - +
B
siCHKA
+ GEE
DDP-treated Doxorubicin-treated
- +                        + 
- - + 
siCHKA - +                          + 
- - + 
siCHKA
+ GEE
DDP-treated Doxorubicin-treated
- +                         + 
- - + 
siCHKA
+ GEE
- +                         + 
- - + 
INTOV11
SKOV3
+ GEE
Alterations of choline phospholipid metabolism in ovarian cancer: study of the activity and 
expression of choline kinase as a prognostic value. 
 
69 
 
 
 
 
Figure 22: ROS levels and drug sensitivity are affected by modulations of intracellular 
GSH content mimicking CHKA silencing and/or expression. 
C. Effects of GEE exposure on cell sensitivity to DDP and doxorubicin in INTOV11 and 
SKOV3 siCHKA-cells. 
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Figure 23: Alteration of Glutathione metabolism following CHKA silencing is a 
characteristic only of EOC tumoral cells 
A: Quantification of GSH/GSSG ratio in I64-hTERT normal ovarian cell line and in a pool of 
EOC cells. B: Quantification of GSH concentration, in I64-hTERT CHKA transiently silenced 
and control cells. C: Sensitivity to DDP in CHKA silenced I64-hTERT. 
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Figure 24: Effects of depletion and rescue of GSH  in non tumoral  I64-hTERT cells upon 
CHKA silencing. 
A: Effects of BSO treatment on sensitivity to  cisplatinum (DDP)  of I64-hTERT  wild type 
cells. Mean ± SD of growth percentage of treated vs. untreated cells is reported. B: Effects of 
BSO treatment on sensitivity  to  cisplatinum (DDP) of I64-hTERT  control and silenced cells. 
Mean ± SD of growth percentage of treated vs. untreated cells is reported. C: Quantification of 
GSH concentration at the end of 72h of silencing, after GEE loading and at relapse. D: Effects 
of DDP treatment in presence or absence of GEE in siCHKA I64-hTERT cells. Mean ± SD of 
growth percentage of treated vs. untreated cells is reported for 3 independent experiments.  
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Figure 25: ChoKα  detection in EOC surgical specimens 
A: Gene expression analysis of ChoKα in OSE cells, surgical EOC specimens and EOC cell 
lines. Horizontal bars represent relative median expression for each group. B: Western blot 
analyses of total lysates of EOC surgical specimens and OSE cells are shown for ChoKα 
protein expression; β-actin was used as internal loading control. 
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Table 5: Characteristics of publicly available gene-expression EOC datasets 
  
DATASETS
EOC 
TUMOR 
CELLS
NORMAL 
EOC CELL 
LINES 
LMP
TUMORS
LOW
GRADE 
TUMORS
HIGH 
GRADE 
TUMORS 
Iorio
(Cancer Res, 2010)
8 2 / / 21
Berchuck
(Clin Cancer Re, 2009)
/ / 19 4 73
King
(Am J Surg Pathol, 2011)
/ 6 8 13 22
Bonome
(Cancer Res, 2008)
/ 10 / / 185
Bowen
(BMC Med Genomics,
2010)
/ 12 / 2 10
Mok
(Cancer Cell, 2009)
/ 10 / / 53
Anglesio
(Mol Cancer Res, 2008) 
/ / / 30 60
Tothill
(Clin Cancer Res, 2008)
/ / 18 10 210
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Figure 26 : Metanalysis of  metabolism-related genes expression in high grade serous EOC 
vs OSE 
Heat map of differentially expressed metabolism-related genes in EOC. Unsupervised 
hierarchical clustering was performed on gene expression profiles of three different datasets: 
Bowen  (GSE14407, Affy HGU133 plus2;), Mok (GSE18520, Affy HGU133 plus2) and 
Bonome (GSE26712, Affy HGU133A). Samples were selected according to the following 
criteria: 12 OSE and 12 EOC for Bowen dataset, 10 OSE and 10 EOC for Mok and Bonome 
datasets.  Each column represents a tumor sample and each row represents a gene Red color 
indicates genes that were upregulated and green color indicates genes that were downregulated. 
Black indicates genes whose expression is unchanged in tumors as compared to normal 
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Figure 27: Metanalysis of  metabolism-related genes LMP vs MAL tumors 
A: Heat map of differentially expressesed metabolism-related genes in LMP vs malignant 
(MAL) EOC. Unsupervised hierarchical clustering was performed on gene expression profiles 
of tumor specimens selected from Anglesio dataset. Each column represents a tumor sample 
and each row represents a gene Red color indicates genes that were upregulated and green color 
indicates genes that were downregulated. Black indicates genes whose expression is unchanged 
in malignant EOC compared to LMP. B: Box-plot of CHKA and CHKB gene expression data 
from Anglesio dataset comparing LMP vs malignant EOC. Expression values are indicated in 
the boxes as the median of each group. Y-axis probe set expression values in log2 scale. 
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Figure 27: Metanalysis of  metabolism-related genes LMP vs MAL tumors 
C: Heat map of differentially expressesed metabolism-related genes in LMP vs malignant 
(MAL) typeI and type II EOC in Tothill dataset. Unsupervised hierarchical clustering was 
performed on gene expression profiles of tumor specimens. Each column represents a tumor 
sample and each row represents a gene. Red color indicates genes that were upregulated and 
green color indicates genes that were downregulated. Black indicates genes whose expression is 
unchanged in malignant EOC compared to LMP. 
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Figure 28: Evaluation of CHK genes expression according to EOC grading in others 
publicly available datasets 
Box-plot of CHKA and CHKB gene expression data from three different datasets including 
OSE cells (only King dataset), LMP, Low Grade and High Grade  EOC tumors (King, Berchuck 
and Tothill Datasets).  Expression values are indicated in the boxes as the median of each 
group. Y-axis probe set expression values in log2 scale.  
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